June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Modifiable risk factors for diabetic retinopathy (DR) and macular edema (DME) in children with type 1 diabetes (T1D)
Author Affiliations & Notes
  • Konstantina Sampani
    Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States
    Medicine, Harvard Medical School, Boston, Massachusetts, United States
  • Cris Martin Jacoba
    Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States
  • Catherine Gilbert
    Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States
    Tulane University School of Medicine, New Orleans, Louisiana, United States
  • Joyce Keady
    Pediatric, Adolescent and Young Adult Section, Joslin Diabetes Center, Boston, Massachusetts, United States
  • Paolo S Silva
    Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States
  • Lori Laffel
    Pediatric, Adolescent and Young Adult Section, Joslin Diabetes Center, Boston, Massachusetts, United States
    Pediatrics, Harvard Medical School, Boston, Massachusetts, United States
  • Lloyd Paul Aiello
    Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States
  • Jennifer K Sun
    Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Konstantina Sampani, None; Cris Martin Jacoba, None; Catherine Gilbert, None; Joyce Keady, None; Paolo Silva, Hillrom (F), Optomed (F), Optos (F); Lori Laffel, AstraZeneca (C), Boehringer Ingelheim Pharmaceuticals (C), Dexcom Inc. (C), Dompe (C), Insulogic (C), Janssen Pharmaceuticals (C), Laxmi (C), Lifescan (C), Lilly (C), Medtronic (C), Provention (C); Lloyd Aiello, Kalvista (I), Kalvista (C), Novo Nordisk (C), Optos (F), Optos (R); Jennifer Sun, Adaptive Sensory Technologies (F), Boehringer Ingelheim (F), Kalvista (F), Novo Nordisk (R), Optovue (F), Roche (F), Roche (R)
  • Footnotes
    Support  Research to Prevent Blindness, Massachusetts Lions Eye Research Fund
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1121. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Konstantina Sampani, Cris Martin Jacoba, Catherine Gilbert, Joyce Keady, Paolo S Silva, Lori Laffel, Lloyd Paul Aiello, Jennifer K Sun; Modifiable risk factors for diabetic retinopathy (DR) and macular edema (DME) in children with type 1 diabetes (T1D). Invest. Ophthalmol. Vis. Sci. 2021;62(8):1121.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Although risk factors for DR and DME are well-established in adults with diabetes, they are not as clearly defined in pediatric populations. This study aimed to identify factors associated with DR and DME in a pediatric population with T1D.

Methods : Retrospective chart review was conducted of pediatric (≤21 years old) medical records from the Joslin’s Beetham Eye Institute from 2005-2020. Data collected included demographic characteristics and DR and DME severity. Body mass index (BMI) and blood pressure (BP) were categorized according to CDC sex and age-adjusted growth curves (BMI: under/normal weight (<85th %ile), overweight/obese (≥85th %ile); BP: normal (<90th %ile), elevated/high (≥90th %ile). Analyses were adjusted for correlation between eyes of the same person.

Results : In total, 1735 youth (3454 eyes) were included with mean±SD age 15.4±4.6 yrs, T1D duration 7.1±5.3 yrs, T1D onset 8.3±5.4 yrs, and A1c 8.4±1.3%; 50.7% were female, 30.7% were overweight/obese, and 4.1% had elevated/high BP. DR was present in 8.5% and DME in 1.3% of the eyes. Unadjusted analyses found DR presence was associated with higher A1c (p<.0001), longer T1D duration (p<.0001), younger age of T1D onset (p=0.0002), older attained age (p<.0001), female sex (p=0.001), and elevated/high BP (p<.0001). After backwards elimination modeling, older age (p<.0001), longer T1D duration (p=0.002), and higher A1c (p=0.01) remained significantly associated with DR. In unadjusted analyses, DME was associated with higher A1c (p=0.0003), longer T1D duration (p<.0001), younger age of T1D onset (p=0.02), older age (p<.0001), female sex (p=0.03), elevated/high BP (p=0.002), and obese/overweight BMI (p = 0.03). When adjusting for A1c, T1D duration, age of T1D onset, age, and DR presence, obese/overweight BMI (p=0.04) and elevated/high BP (p=0.04) remained associated with DME.

Conclusions : In this pediatric group with T1D, DR with or without DME was present in 8.5% of eyes. In addition to non-modifiable factors, DR and DME were associated with modifiable systemic risk factors (A1c, BMI, BP). Efforts to optimize these factors in youth from an early age may help reduce adverse ocular outcomes. Future longitudinal studies can assess if early intervention to improve glycemic control, weight, and BP can reduce occurrence of DR and DME in youth with T1D.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×